Navigation Links
Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
Date:9/4/2007

SAN DIEGO, Sept. 4 /PRNewswire/ -- Takeda San Diego announced today that Keith Wilson, Ph.D. has been named president and chief scientific officer (CSO). In this position, he is responsible for overseeing all activities related to Takeda San Diego, Takeda Pharmaceutical Company Limited's U.S.-based drug discovery company.

"Dr. Wilson has been an important part of Takeda San Diego for several years and brings a wealth of scientific excellence to Takeda," said Shigenori Ohkawa, Ph.D., general manager, pharmaceutical research division, Takeda Pharmaceutical Company Limited. "His leadership has been instrumental in focusing the company on drug discovery and building the Takeda San Diego pipeline, and we look forward to his vital contributions in this new role."

Before being named president and CSO at Takeda San Diego, Dr. Wilson served dual roles as vice president of structural biology and vice president of business development. Prior to joining Takeda, he also spent a decade with Vertex Pharmaceuticals co-leading drug discovery programs and significant alliance projects.

Dr. Wilson has formal training in protein X-ray crystallography, and has a doctorate degree in physics from the University of Oregon and a bachelor's degree in physics from Colby College, where he graduated magna cum laude and was awarded the William A. Rogers prize in physics. Dr. Wilson is a contributing author on more than 30 peer-reviewed publications and co-inventor of six issued U.S. patents covering multiple drug candidates.

About Takeda San Diego, Inc.

Takeda San Diego is Takeda's first U.S.-based discovery research operation. Takeda San Diego achieves an advantage in drug discovery by leveraging its leading structural biology capabilities to determine the three dimensional structures of drug targets ahead of competitors and then uses these structures to efficiently create best-in-class drug candidates to treat diabetes, cancer, and other important diseases. Visit http://www.takedasd.com to learn more.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.


'/>"/>
SOURCE Takeda Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. CEO Wilson Defines GEs Health-IT Customer
2. Bruce Maas named CIO at UW-Milwaukee
3. Three finalists named for UW-Madison CIO
4. Eight lawmakers named to Speakers IT task force
5. Hospital named for Madame Curie installs TomoTherapy system
6. Two UW-Madison professors named to National LambdaRail Networking Research Council
7. UW researcher named top innovator
8. Alzheimers drug firm and more winners named in Wisconsin business-plan contest
9. Inacom named Microsofts favorite learning solutions partner of the year
10. Five Wisconsin CIOs named top in nation
11. Deltanoid named to top-15 list of biotech companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):